Hexima

HXL.AX

Tags: AU Healthcare Biotechnology

Hexima Limited Price (HXL.AX)

Stock Price

Low: Year Low

High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Shares Outstanding

167,039,629

(0)%

Market Cap of Hexima (HXL.AX)

Market cap:

As of , HXL.AX has a market cap of . This makes HXL.AX the 1902th most valuable company in the AU by market cap. Market capitalization, or market cap, is the total value of a company's outstanding shares of stock, calculated by multiplying the current stock price by the total number of shares.

Year

Beginning Of Year

End Of Year

YOY Change

Community Sentiment 0 votes

↑ 0% ↓ 0%

Description

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia. Read More

Sector: Healthcare

Previous Close Fetching Data...
Range $0.008-0.021
Market Cap 2.17M
Enterprise Value No Data
Avg Volume Fetching Data...
P/E Ratio Fetching Data...
Dividend Yield Fetching Data...

Industry: Biotechnology

ceo: Mr. Geoffrey Paul Kempler B.Sc.
IPO Date: November, 30, 2020
Country: AU
Currency: AUD
Headquaters: Preston, VIC
Employees: No Data

- Revenue from each product or segment:

Product or Segment	Value:	% - Total	Last 3Y:

- Revenue by Region

Product or Segment	Value:	% - Total	Last 3Y: